Bristol Myers Squibb expects to fund the repurchases with cash on-hand. Approximately 85 percent of the shares to be repurchased under the ASR transactions will be received by Bristol Myers Squibb on August 10, 2023. The total number of shares ultimately repurchased under the ASR transactions will be determined upon final settlement and will be based on a discount to the volume-weighted average price of Bristol Myers Squibb's common stock during the terms of the ASR transactions. Bristol Myers Squibb anticipates that these ASR transactions will be settled during the fourth quarter of 2023. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.